Glutamate in neurologic diseases

J Child Neurol. 1997 Nov;12(8):471-85. doi: 10.1177/088307389701200802.

Abstract

Excitotoxicity has been implicated as a mechanism of neuronal death in acute and chronic neurologic diseases. Cerebral ischemia, head and spinal cord injury, and prolonged seizure activity are associated with excessive release of glutamate into the extracellular space and subsequent neurotoxicity. Accumulating evidence suggests that impairment of intracellular energy metabolism increases neuronal vulnerability to glutamate which, even when present at physiologic concentrations, can damage neurons. This mechanism of slow excitotoxicity may be involved in neuronal death in chronic neurodegenerative diseases such as the mitochondrial encephalomyopathies, Huntington's disease, spinocerebellar degeneration syndromes, and motor neuron diseases. If so, glutamate antagonists in combination with agents that selectively inhibit the multiple steps downstream of the excitotoxic cascade or help improve intracellular energy metabolism may slow the neurodegenerative process and offer a therapeutic approach to treat these disorders.

Publication types

  • Review

MeSH terms

  • Acute Disease
  • Animals
  • Brain Injuries / physiopathology
  • Brain Ischemia / physiopathology
  • Child
  • Child Development
  • Chronic Disease
  • Disease Models, Animal
  • Epilepsy / physiopathology
  • Glutamic Acid / adverse effects
  • Glutamic Acid / physiology*
  • Humans
  • Nervous System Diseases / drug therapy
  • Nervous System Diseases / physiopathology*
  • Neurodegenerative Diseases / physiopathology
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use
  • Receptors, AMPA / physiology
  • Receptors, N-Methyl-D-Aspartate / physiology

Substances

  • Neuroprotective Agents
  • Receptors, AMPA
  • Receptors, N-Methyl-D-Aspartate
  • Glutamic Acid